{"id":"W3043703771","doi":"10.1056/nejmoa1910836","title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3708,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Eisai; National Institute for Health and Care Research; Plexxikon; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Sanofi Genzyme; Pfizer; Incyte; National Cancer Institute; LEO Pharma; Massachusetts Medical Society; Regeneron Pharmaceuticals; Sanofi; GlaxoSmithKline; Amgen; Les Laboratories Pierre Fabre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Melanoma; Medicine; Oncology; Internal medicine; Metastatic melanoma; Immunotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}